HUMULIN 70/30 (insulin human) by Eli Lilly and Company. Approved for insulin [epc]. First approved in 1989.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
HUMULIN 70/30 is a fixed-combination human insulin injection containing 70% NPH (intermediate-acting) and 30% regular (rapid-acting) insulin for subcutaneous administration. It is indicated for the treatment of diabetes mellitus in patients requiring insulin therapy. This combination formulation provides both basal and mealtime insulin coverage in a single injection.
As a decades-old product approaching loss of exclusivity with moderate competitive pressure (30/100), this brand faces declining revenue and team consolidation risk.
Insulin
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Comparing Insulin Aspart With Fast-acting Insulin Human in Subjects With Type 1 Diabetes
Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Type 1 Diabetics
Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Healthy Subjects.
Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Novolin R, in Healthy Subjects.
Worked on HUMULIN 70/30 at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on HUMULIN 70/30 offers limited career acceleration due to the product's mature lifecycle and approaching loss of exclusivity. Roles available are primarily defensive (account management, pricing strategy, formulary protection) rather than growth-oriented, making this assignment suitable for experienced professionals managing decline rather than launching growth initiatives.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo